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論文の要旨 
Abstract of thesis 
 
In this doctoral dissertation, Vo Van Anh describes the role of DNAM-1 expressed on inflammatory monocytes in 
the exacerbation of acute kidney injury. The summary is as follows: 
 
Purpose 
Acute kidney injury (AKI) is a life-threatening syndrome, commonly seen in hospitalized patients. AKI could result 
in death or chronic complications even after recovery. Inflammation following the initial injury exaggerates the 
disease progression, in which myeloid cells such as monocytes and neutrophils, play critical causative roles. Thus, 
targeting myeloid cell activation and migration gives a protective effect in AKI. DNAM-1 is a co-stimulatory 
immunoreceptor, expressed on human and mice NK cells, CD4+ T cells, CD8+ T cells, subsets of macrophages, 
monocytes and B cells. Initial studies by Akira Shibuya showed that DNAM-1 activates the cell-mediated 
cytotoxicity and cytokines production of NK cells and CD8+ T cells. However, its contribution to myeloid cells, 
including monocytes, are not fully understood. Therefore, this study aimed to elucidate the following points; first, 
expression pattern of DNAM-1 on myeloid cells in human and mice peripheral blood in comparison with that in the 
spleen, which was already reported; second, the function of DNAM-1 expressing on myeloid cells; third, involvement 
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 of DNAM-1 in acute kidney injury, the disease condition wherein myeloid cells play the key roles. The applicant 
also intended to research the mechanism by which DNAM-1 performs its disease regulation. 
 
Materials and methods 
DNAM-1 expression on immune cells was analyzed by flow cytometry. First, blood from healthy donors was used 
to isolate human immune cells, while mice blood and spleens were used to prepare murine cells. Then, isolated cells 
were fluorescently labeled using antibodies specific for differential cell surface markers and DNAM-1. Therefore, 
DNAM-1 expression on different populations of cells could be acquired. The physiological function of DNAM-1 in 
inflammatory monocytes was examined using an in vitro adherence assay. 5(6)-Carboxyfluorescein N-
hydroxysuccinimidyl ester (CFSE)-labeled inflammatory monocytes were incubated with CD155 – the stress-
induced ligand of DNAM-1 – transfected cells. After washing, remaining CFSE positive adhered cells were 
quantified using Keyence microscopy. A murine model of unilateral warm ischemia-reperfusion injury (IRI) 
resembles AKI in human. It was made to explore the in vivo physiological function of DNAM-1. In brief, mice were 
anesthetized, and their right kidneys were cut-off while the left kidneys were clamped to induce ischemia. After a 
particular time, releasing clamps initiated the reperfusion of blood, and kidney injury progressed. The renal 
dysfunction was measured by plasma creatinine and blood urine nitrogen. To investigate whether DNAM-1 promoted 
AKI via regulating monocytes migration from blood to tissue, several strategies were used. First, monocytes 
accumulated in kidneys after IRI were quantified by flow cytometry. Next, inflammatory cytokines produced by 
sorted monocytes from organs were measured by quantitative PCR. The systemic cytokines increased after IRI was 
detected in the plasma by cytometric bead array. 
 
Results 
Firstly, this study comprehensively investigated the DNAM-1 expression pattern in peripheral blood cells, in 
comparison with that of the previously reported splenocytes. It revealed that the expression of DNAM-1 is selective 
on the inflammatory monocytes but not patrolling monocytes; which was conserved in both human and mouse, 
suggesting DNAM-1 is an evolutionary molecule in inflammatory monocytes. Neutrophils and eosinophils also 
express DNAM-1 at a moderate level, which was not seen in splenocytes; however, lymphoid cells express DNAM-
1 at the level as much as observed in spleen, suggesting cell type-specific and tissue-specific characteristics of 
DNAM-1 expression. DNAM-1 deficient (CD226-/-) inflammatory monocytes has attenuated ability to adhere to 
CD155, DNAM-1 ligand, expressed on transfected cells in vitro compared to wild type (WT) cells. Supportively, 
inhibiting DNAM-1 and CD155 interaction by monoclonal antibodies also lowered the adhered cell number in the 
adherence assay compared with isotype control. These data suggested that DNAM-1 – CD155 interaction is required 
for inflammatory monocytes mobility characteristics, particularly the adhesion behavior. DNAM-1 deficient mice 
showed milder renal dysfunction induced by IRI in comparison with WT mice, indicating DNAM-1 exaggerated 
acute kidney injury. Furthermore, the accumulation of immune cells following ischemia-reperfusion including 
monocytes and neutrophils were reduced in CD226-/- mice, suggesting that DNAM-1 promoted inflammation in 
AKI. 
 
 
 Discussion 
Although DNAM-1 expression on lymphoid cells was consistent between organs, it was diverse in myeloid cells, 
depending on cell types and tissue specificity. Myeloid cells are highly heterogeneous with multiple subsets in an 
organ. So, DNAM-1 could be one of those molecules which determine expression patterns and the physiological 
distinction between subgroups, to be specific in monocytes sub-populations in this study. It is of interest to identify 
which master regulator determines DNAM-1 expression, developmental window and functional requirement of 
DNAM-1 on myeloid sub-types. DNAM-1 function on monocytes’ migration was reported in human cells in vitro, 
but this was the first to describe DNAM-1 involvement in mouse monocytes' adherence, which is corroborating with 
previous data of human cells, suggesting DNAM-1 knockout mice as a useful tool to investigate physiological 
function of DNAM-1 in murine disease models. Even though CD155 transfected cells were used for the functional 
in vitro assay, primary cells, including endothelial cells, also express CD155. Also, the expression was reported to 
upregulate in stress-induced conditions, including tissue damage. Therefore, DNAM-1 expressing inflammatory 
monocytes might interact with CD155 expressing on endothelial cells for the trans-endothelial extravasation after 
IRI induction in this study. There exists a correlation between attenuated kidney injury and the decrease of myeloid 
cells percentage and number in the injured site. Whether DNAM-1 promoted IRI induced inflammation by directly 
regulating myeloid cells migration is unclear, despite the dependency of monocytes adhesion on DNAM-1 in vitro. 
Therefore, other possibilities should be examined such as DNAM-1 regulated inflammatory cytokines production or 
DNAM-1 indirectly controlling myeloid cell migration via different cell types. Though this study showed that 
DNAM-1 possesses a pathogenic effect in the acute phase of kidney injury, it is unknown what would happen at the 
late stage of this model. For instance, whether chronic kidney inflammation such as fibrosis, could be altered by 
DNAM-1 deficiency. Also, it is of interest to investigate DNAM-1 involvement in other ischemia-related diseases 
such as brain stroke and heart attack. 
 
審査の要旨 
 Abstract of assessment result 
 
【批評 Review】 
In this thesis research, Vo Van Anh found the expression of DNAM-1 on inflammatory monocytes and showed 
that DNAM-1 knockout mice have milder acute kidney injury indicating the exacerbating role of DNAM-1 in acute 
kidney injury. Research design is interesting and feasible, data are clear and convincing, discussion and future plans 
are reasonable and the manuscript was written in an appropriate style and quality.  
 
【最終試験の結果 Result】 
The final examination committee conducted a meeting as a final examination on 03/06/2019. The applicant 
provided an overview of dissertation, addressed questions and comments raised during Q&A session. All of the 
committee members reached a final decision that the applicant has passed the final examination. 
 
【結論 Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be awarded a Doctor 
of Philosophy in Human Biology. 
